Maxeler Technologies Licenses Healthcare Technologies

1
Maxeler Technologies Licenses Healthcare
Technologies
1888PressRelease - Maxeler Technologies (London,
UK), a leader in optimization of computational
data movement, is collaborating with Professor
Ophir Frieder at Georgetown University
(Washington DC, USA) to commercialize Georgetown
AI research aimed at reducing patient adverse
effects related to errors in drug prescriptions,
on Maxelers M-Space Software Delivery
Platform. Maxeler Technologies recently licensed
novel, explainable AI-driven prescription
prediction technologies from Georgetown
University. Using the patent-pending, technology
developed at Georgetowns Information Retrieval
Laboratory under Professor Ophir Frieder, Maxeler
intends to work with the researchers at
Georgetown to productize scalable,
patient-specific, prescription selectors,
reducing drug resistance, thereby improving
patient care. Frieder, the Robert L. McDevitt,
K.S.G., K.C.H.S. and Catherine H. McDevitt
L.C.H.S. Professor in Computer Science and
Information Processing, is the lead inventor of
the technology. The AI-driven prescription
predictive models suggest effective medications
that minimize adverse effects. Many artificial
intelligence based efforts focus on the
aforementioned problem but do so using black
box approaches which solve the problem, but fail
to provide interpretability. Since prescribing
physicians are hesitant to rely on suggestions
whose derivations are not understood, the lack of
interpretability renders the results of the black
box AI unuseable. Frieder and his collaborators
solved that problem by making the recommendations
explainable. High dimensional information and
temporal event relationships complicate the
development of predictive models. Traditional
approaches transform and flatten electronic
health records into vector representations that
ignore medical event temporal relationships,
reducing prediction accuracy.
2
The explainable approach automatically
restructures each patients electronic medical
record into a graph and utilizes a graph-kernel
approach to formulate prescription predictions.
As graphs are easily understood both by doctors
and patients, the developed system will provide
comprehensible explanations of why a particular
medication is prescribed. The products are
expected to address domestic and international
markets. Maxeler intends to propose using
medical records from a national health service to
start adapting the research models to real-world
data. Our goal is to develop a model to process
electronic medical records relying on proven,
scalable, data-mining techniques, yielding a
nearly real-time, personalized, clinically
explainable drug prediction approach, says Oskar
Mencer, CEO of Maxeler Technologies. Antibiotic
prescriptions will be the initial focus. This is
because real-time personalized prescriptions are
needed as resistance to antibiotics is
personalized and develops over time. As Frieder
explains, This partnership with Maxeler provides
us with the opportunity to move our research from
the abstract to clinical practice, hopefully
globally improving patient care. http//maxeler.
com/news/2020/maxeler-licenses-healthcare-technolo
gies.html About Maxeler Technologies Maxeler
Technologies is one of the worlds leading
companies with tools and services for software
transformation, optimization of data movement and
data representation, in High Performance
Computing on standard CPUs as well as computing
hardware for specific mission critical domains.
Maxeler solutions including Cybersecurity, AI,
Risk and Imaging have been used in production in
Finance, Oil-and-Gas, Government and Academic
Research.